Sunovion Pharmaceuticals, Inc. manufactures pharmaceutical products. The Company develops and produces medicines for the treatment of central nervous system and respiratory ailments such as schizophrenia, depression, epilepsy, neuropathic pain, and insomnia. Sunovion Pharmaceuticals serves customers in the United States.
In India, the Pharmaceutical business of Sunovion Pharmaceuticals, Inc. is focused on Crystal forms, Nonracemic mixtures, 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders, Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine.
Sunovion Pharmaceuticals, Inc. filed patent application numbered 6075/DELNP/2013 that is titled as HETEROARYL COMPOUNDS. This patent application has been granted as Patent Number 316796.
The invention covers chemical compounds. Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the claims 1-35 of the application falls under section 3(d) of the Patents Act as these claims don’t show any efficacious data neither in terms of technical advancement nor in terms of economical or environmental advancement.
As a response to said objection, the applicant responded by submitting that the amended set of claims disclose novel heteroaryl compound which are useful for treating and/or management of various disorders, such as CNS disorders and metabolic disorders and also modulate the activity of PDE enzyme. The specification discloses the surprising potency of the compounds of the present invention to inhibit human and therapeutic effects.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
